PURPOSE: This study sought to evaluate the reproducibility of [(11)C]choline-positron emission tomography and the effect of trastuzumab in breast cancer. EXPERIMENTAL DESIGN: Twenty-one patients with newly diagnosed and recurrent breast cancer stage II-IV had a baseline dynamic [(11)C]choline-PET scan, 10 patients had a second [(11)C]choline-PET scan to examine reproducibility, and 6 patients had a second scan within a month after trastuzumab. Analysis of [(11)C]choline uptake was measured as the semiquantitative standardized uptake value at 30 and 60 minutes (SUV(30) and SUV(60)), and quantitatively as the net irreversible retention of the radiotracer at steady-state (Ki) and plasma to tissue exchange at 60 minutes (IRF60min). RESULTS: Breast tumor lesions in all patients were visualized by [(11)C]choline PET. The difference in tumor versus normal tissue uptake was significant for SUV(30), SUV(60), Ki, and IRF60 minutes (Wilcoxon P < 0.0001). At 60 minutes postinjection, 15.1 +/- 2.16% of plasma radioactivity was due to unmetabolized [(11)C]choline radioactivity. [(11)C]Choline uptake was reproducible in breast tumor lesions (r(2) = 0.9 for SUV, 0.9 for Ki, and 0.8 for IRF60). Early responses to trastuzumab measured by [(11)C]choline-PET were significant in three lesions occurring in two patients who responded clinically. CONCLUSIONS: [(11)C]Choline-PET uptake variables can be reproducibly assessed. Initial studies show that trastuzumab decreases [(11)C]choline uptake.
PURPOSE: This study sought to evaluate the reproducibility of [(11)C]choline-positron emission tomography and the effect of trastuzumab in breast cancer. EXPERIMENTAL DESIGN: Twenty-one patients with newly diagnosed and recurrent breast cancer stage II-IV had a baseline dynamic [(11)C]choline-PET scan, 10 patients had a second [(11)C]choline-PET scan to examine reproducibility, and 6 patients had a second scan within a month after trastuzumab. Analysis of [(11)C]choline uptake was measured as the semiquantitative standardized uptake value at 30 and 60 minutes (SUV(30) and SUV(60)), and quantitatively as the net irreversible retention of the radiotracer at steady-state (Ki) and plasma to tissue exchange at 60 minutes (IRF60min). RESULTS:Breast tumor lesions in all patients were visualized by [(11)C]choline PET. The difference in tumor versus normal tissue uptake was significant for SUV(30), SUV(60), Ki, and IRF60 minutes (Wilcoxon P < 0.0001). At 60 minutes postinjection, 15.1 +/- 2.16% of plasma radioactivity was due to unmetabolized [(11)C]choline radioactivity. [(11)C]Choline uptake was reproducible in breast tumor lesions (r(2) = 0.9 for SUV, 0.9 for Ki, and 0.8 for IRF60). Early responses to trastuzumab measured by [(11)C]choline-PET were significant in three lesions occurring in two patients who responded clinically. CONCLUSIONS: [(11)C]Choline-PET uptake variables can be reproducibly assessed. Initial studies show that trastuzumab decreases [(11)C]choline uptake.
Authors: Milan Grkovski; Karem Gharzeddine; Peter Sawan; Heiko Schöder; Laure Michaud; Wolfgang A Weber; John L Humm Journal: J Nucl Med Date: 2018-04-06 Impact factor: 10.057
Authors: Oluwaseun A Odewole; Oyeladun A Oyenuga; Funmilayo Tade; Bital Savir-Baruch; Peter T Nieh; Viraj Master; Zhengjia Chen; Xiaojing Wang; Ashesh B Jani; Leah M Bellamy; Raghuveer K Halkar; Mark M Goodman; David M Schuster Journal: Mol Imaging Biol Date: 2015-04 Impact factor: 3.488
Authors: Milan Grkovski; Zachary A Kohutek; Heiko Schöder; Cameron W Brennan; Viviane S Tabar; Philip H Gutin; Zhigang Zhang; Robert J Young; Bradley J Beattie; Pat B Zanzonico; Jason T Huse; Marc K Rosenblum; Ronald G Blasberg; John L Humm; Kathryn Beal Journal: Eur J Nucl Med Mol Imaging Date: 2019-12-21 Impact factor: 9.236
Authors: Ella F Jones; Deep K Hathi; Rita Freimanis; Rita A Mukhtar; A Jo Chien; Laura J Esserman; Laura J Van't Veer; Bonnie N Joe; Nola M Hylton Journal: Cancers (Basel) Date: 2020-06-09 Impact factor: 6.575